Gary Glick puts Odyssey's $218M cash stack to use, ac­quir­ing ma­chine learn­ing out­fit

Around the same time se­r­i­al en­tre­pre­neur Gary Glick was putting to­geth­er his lat­est (and biggest yet) ven­ture, Odyssey Ther­a­peu­tics this past March, a mentee in­tro­duced him to a young Lon­don-based com­pa­ny work­ing on ap­ply­ing ma­chine learn­ing to drug dis­cov­ery.

Rahko, found­ed just three years ago by a few ma­chine learn­ing ex­perts, was de­vel­op­ing a plat­form right up Glick’s al­ley: Odyssey, as he’s con­ceived it, would ex­e­cute on drug dis­cov­ery at top speed just like IFM and Scor­pi­on, his pre­vi­ous star­tups, but do it with a heavy dose of da­ta sci­ence.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER